Quantcast

Latest Imatinib Stories

2008-06-09 06:00:38

Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced that Portland, Ore.-based Oregon Health & Science University (OHSU) Cancer Institute has purchased a MassARRAY(R) system for use in the discovery, development and testing of biomarker panels for rapid classification and characterization of cancer. The OHSU Cancer Institute is recognized worldwide for its cancer research. "This placement at the prestigious OHSU Cancer Institute is a tremendous...

2008-06-05 03:00:07

By Edwards, Michael A Beatty, John S; Shah, Malay B; Bittner, James G IV To the Editor: Non-epithelial mesenchymal tumors, including gastrointestinal stromal tumors (GISTs) and smooth muscle tumors (SMTs), are rare and may occur in any part of the alimentary tract.1 GISTs originate from the interstitial cell of Cajal, an intestinal pacemaker cell, and represent 1 per cent to 3 per cent of all gastrointestinal malignant tumors. Approximately 5 per cent of GISTs occur in the colon and rectum...

632e85fdf2a7b2b8406f7bac0448b4db
2008-03-06 10:30:00

According to new research, use of the cancer drug Gleevec may cause fertility complications in some women.Dr. Constantinos Christopoulos of the Amalia Fleming General Hospital in Athens and colleagues published the recent study of the drug, generically known as imatinib, in the New England Journal of Medicine. The team studied the case of a 30-year-old woman with chronic myeloid leukemia (CML). After taking Gleevec for two years, the woman stopped menstruating. They also noted a reduction of...

2007-05-18 06:00:37

By Patnaik, Mrinal M; Rindos, Michelle; Kouides, Peter A; Tefferi, Ayalew; Pardanani, Animesh Context.-Systemic mastocytosis is characterized by abnormal growth and accumulation of neoplastic mast cells in various organs. The clinical presentation is varied and may include skin rash, symptoms related to release of mast cell mediators, and/or organopathy from involvement of bone, liver, spleen, bowel, or bone marrow. Objective.-To concisely review pathogenesis, disease classification,...

2006-12-06 18:02:44

By ED SUSMAN After five years of treatment nearly 90 percent of leukemia patients treated with Gleevec are still alive -- an outcome barely conceivable before the drug was discovered. The Gleevec story truly is a triumph of science over disease, Brian Druker, the lead investigator of the studies with the anti-cancer drug, told United Press International Wednesday. Druker, professor of medicine at the Oregon Health and Sciences University Cancer Center in Portland, said, The results we...

2006-07-23 14:45:00

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage,...

89d7ddf2b7a291cf1da22844fcc1d77b1
2006-07-23 12:05:00

By Maggie Fox, Health and Science Correspondent WASHINGTON -- Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage, the team...

2006-06-28 17:19:35

WASHINGTON (Reuters) - A new Bristol-Myers Squibb Co. pill won U.S. approval for fighting two types of leukemia in patients running out of treatment options, the company said on Wednesday. The drug called Sprycel was shown to help some patients with chronic myeloid leukemia (CML) that had stopped responding to Novartis AG's pill Gleevec. Bristol-Myers said it expects to have the drug on the market within days. In addition to CML, the FDA approval covers treatment of adults with...

2006-06-15 05:20:00

By Gene Emery BOSTON -- Two new drugs may help treat some adult cases of leukemia that fail to respond to Novartis AG's Gleevec, two studies showed on Wednesday. One drug, dasatinib, an experimental Bristol-Myers Squibb drug recently endorsed by a Food & Drug Administration advisory panel, could receive full approval by the end of June. Dasatinib helped 68 out of 84 volunteers suffering from a form of chronic myeloid leukemia, or CML, that was resistant to Novartis's Gleevec, according...

2006-06-14 16:17:58

By Gene Emery BOSTON (Reuters) - Two new drugs may help treat some adult cases of leukemia that fail to respond to Novartis AG's Gleevec, two studies showed on Wednesday. One drug, dasatinib, an experimental Bristol-Myers Squibb Co. drug recently endorsed by a Food & Drug Administration advisory panel, could receive full approval by the end of June. Dasatinib helped 68 out of 84 volunteers suffering from a form of chronic myeloid leukemia, or CML, that was resistant to...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related